| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
REVENUES: | ||||||
Total revenues | ||||||
1,728 | 1,396 | 1,404 | ||||
Cost of sales | ||||||
244 | 364 | 168 | ||||
Gross profit | ||||||
1,484 | 1,032 | 1,236 | ||||
OPERATING EXPENSES: | ||||||
Research and development | ||||||
5,904 | 5,830 | 5,784 | ||||
Acquired in-process research and development | ||||||
- | 800 | - | ||||
General and administrative | ||||||
8,139 | 5,647 | 3,869 | ||||
Total operating expenses | ||||||
-14,043 | -12,277 | 9,653 | ||||
Gain on sale of assets | ||||||
- | - | 1,754 | ||||
Loss from operations | ||||||
-12,559 | -11,245 | -6,663 | ||||
OTHER INCOME/(EXPENSES): | ||||||
Interest income (expense), net | ||||||
29 | 116 | -12 | ||||
Gain on sale of equity method investment in Ascendance | ||||||
- | 3,215 | - | ||||
Other income, net | ||||||
294 | 183 | 38 | ||||
Total other income (expense), net | ||||||
323 | 3,514 | 26 | ||||
NET LOSS BEFORE INCOME TAXES | ||||||
-12,236 | -7,731 | - | ||||
Income tax provision | ||||||
148 | - | - | ||||
NET LOSS | ||||||
-12,384 | -7,731 | -6,637 | ||||
Net loss attributable to noncontrolling interest | ||||||
-230 | -229 | -57 | ||||
NET LOSS ATTRIBUTABLE TO AGEX | ||||||
-12,154 | -7,502 | -6,580 | ||||
NET LOSS PER COMMON SHARE: BASIC AND DILUTED | ||||||
-0.33 | -0.21 | -0.21 | ||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED | ||||||
37,271 | 34,914 | 30,644 | ||||
Subscription and Advertisement Revenues [Member] | ||||||
Total revenues | ||||||
1,332 | 1,227 | - | ||||
Total revenues | ||||||
- | - | 1,399 | ||||
Service and Other Revenues [Member] | ||||||
Total revenues | ||||||
- | - | 5 | ||||
Grant Revenues [Member] | ||||||
Total revenues | ||||||
180 | 20 | - | ||||
Other Revenues [Member] | ||||||
Total revenues | ||||||
216 | 149 | - | ||||